BMS-564929

CaptionSynonyms

BMS-564929

Drug Information
Image
Identifiers ChemSpider ID UNII KEGG ChEBI ChEMBL		Chemical Data C H N O

BMS-564929 is an experimental androgen receptor agonist that is being studied for its potential use in the treatment of conditions such as muscle wasting and osteoporosis. Developed by Bristol-Myers Squibb, this compound belongs to a class of tissue-selective androgen receptor modulators (SARMs), which are intended to have the same beneficial effects as anabolic steroids but with fewer side effects.

Development and Mechanism

BMS-564929 was developed as part of a research program aimed at finding a safe and effective alternative to traditional anabolic steroids. These substances often come with significant side effects, including but not limited to, cardiovascular issues, hormonal imbalances, and liver damage. SARMs like BMS-564929 are designed to selectively target and activate the androgen receptors in specific tissues such as muscle and bone, thereby potentially reducing unwanted systemic effects.

The mechanism of action of BMS-564929 involves binding to the androgen receptor with high affinity and selectivity. By selectively activating these receptors in muscle and bone tissue, BMS-564929 aims to promote muscle growth and bone density without the adverse effects typically associated with steroid use, such as virilization or impact on prostate health.

Clinical Trials and Research

As of the last update, BMS-564929 has undergone preliminary clinical trials to evaluate its efficacy and safety. The results from these studies have suggested that BMS-564929 has a favorable anabolic effect on muscle tissue and bone density with minimal side effects. However, detailed results and further studies are necessary to fully understand the therapeutic potential and safety profile of this compound.

Potential Applications

The primary potential applications of BMS-564929 include treatment for diseases associated with muscle and bone degeneration such as muscle wasting diseases, osteoporosis, and possibly in the management of conditions like sarcopenia in elderly populations. Additionally, its use could be explored in other medical areas where muscle and bone strength are compromised.

Regulatory Status

As BMS-564929 is still in the experimental stages, it has not yet been approved for clinical use by any major regulatory bodies, including the Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Its development and potential market introduction depend on the outcomes of ongoing and future clinical trials.

See Also

• Selective androgen receptor modulator
• Anabolic steroid
• Osteoporosis
• Muscle wasting